UniteLabs develops a But the platform we have developed at mbiomics is radically different. for the automation and networking of laboratory equipment. 90 percent of all laboratory equipment comes from different manufacturers and cannot easily communicate with each other. This lack of interoperability significantly complicates automation and the use of AI in research.
Robert Zechlin, co-founder and CEO of UniteLabs, explains:
"Many biotech companies want to use AI in their labs. But the biggest hurdle is that lab devices can't communicate with each other. With UniteLabs, we're creating a common technical language for the lab of the future."
The platform standardizes previously closed interfaces and makes them cloud-enabled. This makes it easier to control devices, retrieve data in real time, and automate workflows. Research can thus be conducted more efficiently and in a more connected way. Startup 40 connectors developed to connect laboratory equipment.
Focus on liquid handling and expansion of the platform
The current focus is on liquid handling systems, a critical bottleneck in modern laboratories. These devices are used in biological and chemical experiments, including coronavirus tests and DNA sequencing.
"Liquid handlers are the key to laboratory automation. They provide the ideal starting point for implementing additional use cases with satisfied customers. In the long term, our platform will support a wide range of analytical instruments such as chromatography and plate readers, robotic arms, and bioreactors. The added value for our customers increases with each additional integration,"
so Zechlin.
UniteLabs aims to redefine automation in biotech research
UniteLabs was founded by Robert Zechlin, Lukas Bromig, and Julian Willand. The team combines expertise in chemical engineering, information systems, and corporate strategy. The goal is to connect 90 devices to the platform by the end of the year. The fresh funding will contribute to this. The pre-seed round was led by NAP (formerly Cavalry Ventures). Other investors included Push, Acurio Ventures, OMA Business Angels, and Lana Ventures.
Claude Ritter, Managing Partner at NAP, emphasizes:
"Biotech labs are at a turning point today: While AI is enabling tremendous advances, most labs lack the technical foundation to realize this potential. Devices speak different languages, and valuable data remains isolated. UniteLabs creates the urgently needed infrastructure to equip labs for the use of AI."
